• 
  Gilles Freyer, Anne Floquet, Olivier Tredan, Aurore Carrot, Carole Langlois-Jacques, et al.. Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group. Nature Communications, 2024, 15 (1), pp.1985. ⟨10.1038/s41467-024-45974-w⟩. ⟨hal-04549309⟩
• 
  Coralie Mallebranche, Yves Reguerre, Brice Fresneau, Nicolas Andre, Claire Berger, et al.. The French FRACTURE database: A way to improve knowledge on management of children with very rare tumors. Pediatric Blood and Cancer, 2022, 69 (12), ⟨10.1002/pbc.30003⟩. ⟨hal-04030742⟩
• 
  Lionel Perrier, Frederic Balusson, Magali Morelle, Joël Castelli, Juliette Thariat, et al.. Cost-effectiveness of weekly adaptive radiotherapy versus standard IMRT in head and neck cancer alongside the ARTIX trial. Radiotherapy & Oncology, 2024, Radiotherapy and Oncology : Journal of the European Society For Therapeutic, 193, pp.110116. ⟨10.1016/j.radonc.2024.110116⟩. ⟨hal-04444231⟩
• 
  Roxane Machavoine, Sylvie Helfre, Valérie Bernier, Stéphanie Bolle, Julie Leseur, et al.. Locoregional Control and Survival in Children, Adolescents, and Young Adults With Localized Head and Neck Alveolar Rhabdomyosarcoma-The French Experience.. Frontiers in Pediatrics, 2022, Frontiers in Pediatrics, 9, pp.783754. ⟨10.3389/fped.2021.783754⟩. ⟨hal-04572907⟩
• 
  Guilhem Roubaud, M. Özgüroğlu, Nicolas Penel, N. Matsubara, N. Mehra, et al.. Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study.. European Journal of Cancer, 2022, European Journal of Cancer, 170, pp.73-84. ⟨10.1016/j.ejca.2022.04.016⟩. ⟨hal-04568938⟩
• 
  Anna Gueiderikh, Thomas Sarrade, Youlia M. Kirova, Brigitte de la Lande, Florent de Vathaire, et al.. Radiation-induced lung injury after breast cancer treatment: incidence in the CANTO-RT cohort and associated clinical and dosimetric risk factors. Frontiers in Oncology, 2023, 13, ⟨10.3389/fonc.2023.1199043⟩. ⟨hal-04195134⟩
• 
  Justine Gantzer, Maud Toulmonde, François Séverac, Ali N. Chamseddine, Celine Charon-Barra, et al.. PEC-PRO: A new prognostic score from a series of 87 patients with localized perivascular epithelioid cell neoplasms (PEComas) treated with curative intent. Cancer, 2024, ⟨10.1002/cncr.35277⟩. ⟨hal-04533834⟩
• 
  Renaud Descourt, Maurice Pérol, Gaëlle Rousseau-Bussac, David Planchard, Bertrand Mennecier, et al.. Efficacité et tolérance du brigatinib chez des patients pris en charge pour un cancer bronchopulmonaire non à petite cellules avec translocation ALK en France. Étude BRIGALK.. Congrès de pneumologie de langue française, Jan 2019, Marseille, France. ⟨10.1016/j.rmr.2018.10.039⟩. ⟨hal-02633916⟩
• 
  Renaud Descourt, Maurice Perol, Gaëlle Rousseau-Bussac, David Planchard, Bertrand Mennecier, et al.. Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study). Lung Cancer, 2019, 136, pp.109-114. ⟨10.1016/j.lungcan.2019.08.010⟩. ⟨hal-04529929⟩
• 
  Pauline Parent, Gautier Marcq, Sola Adeleke, Anthony Turpin, Stergios Boussios, et al.. Predictive biomarkers for immune checkpoint inhibitor response in urothelial cancer. Therapeutic Advances in Medical Oncology, 2023, 15, pp.17588359231192402. ⟨10.1177/17588359231192402⟩. ⟨inserm-04521181⟩
• 
  Thibault Butel, Marie Karanian, Gaelle Pierron, Daniel Orbach, Dominique Ranchere, et al.. Integrative clinical and biopathology analyses to understand the clinical heterogeneity of infantile rhabdomyosarcoma: A report from the French MMT committee. Cancer Medicine, 2020, 9 (8), pp.2698-2709. ⟨10.1002/cam4.2713⟩. ⟨hal-03882476⟩
• 
  P. Sargos, J. Le Guevelou, J. Khalifa, L. Albiges, D. Azria, et al.. The role of radiation therapy for de novo metastatic bladder and renal cancers. Cancer/Radiothérapie, 2024, 28 (1), pp.56 - 65. ⟨10.1016/j.canrad.2023.02.004⟩. ⟨inserm-04517309⟩
• 
  Jennifer Le Guevelou, Paul Sargos, Ludovic Ferretti, Stephane Supiot, David Pasquier, et al.. Sexual Structure Sparing for Prostate Cancer Radiotherapy: A Systematic Review. European Urology Oncology, In press, S2588-9311 (23), pp.00163-3. ⟨10.1016/j.euo.2023.08.003⟩. ⟨inserm-04517271⟩
• 
  B. Audinot, D. Drubay, N. Gaspar, A. Mohr, C. Cordero, et al.. ctDNA quantification improves estimation of outcomes in patients with high-grade osteosarcoma: a translational study from the OS2006 trial. Annals of Oncology, 2023, S0923-7534 (23), pp.05113-X. ⟨10.1016/j.annonc.2023.12.006⟩. ⟨inserm-04516533⟩
• 
  Cécile Thomas-Teinturier, Rodrigue Sétchéou Allodji, Ekaterina Svetlova, Marie-Alix Frey, Odile Oberlin, et al.. Ovarian reserve after treatment with alkylating agents during childhood. Human Reproduction, 2015, 30 (6), pp.1437 - 1446. ⟨10.1093/humrep/dev060⟩. ⟨inserm-04439971⟩
• 
  Rodrigue S Allodji, Margaret A Tucker, Michael M Hawkins, Marie‐cécile Le Deley, Cristina Veres, et al.. Role of radiotherapy and chemotherapy in the risk of leukemia after childhood cancer: An international pooled analysis. International Journal of Cancer, 2020, 148 (9), pp.2079 - 2089. ⟨10.1002/ijc.33361⟩. ⟨inserm-04439010⟩
• 
  Grégory Delpon, Alexandre Escande, Timothée Ruef, Julien Darréon, Jimmy Fontaine, et al.. Comparison of Automated Atlas-Based Segmentation Software for Postoperative Prostate Cancer Radiotherapy. Frontiers in Oncology, 2016, 6, ⟨10.3389/fonc.2016.00178⟩. ⟨hal-01683878⟩
• 
  Arthur Petat, Eric Dansin, Fabien Calcagno, Laurent Greillier, Eric Pichon, et al.. Treatment strategies for thymic carcinoma in a real-life setting. Insights from the RYTHMIC network. European Journal of Cancer, 2022, 162, pp.118-127. ⟨10.1016/j.ejca.2021.11.028⟩. ⟨hal-03524368⟩
• 
  Maxime Enault, Véronique Minard-Colin, Nadège Corradini, Guy Leverger, Estelle Thebaud, et al.. Extracranial rhabdoid tumours: Results of a SFCE series of patients treated with a dose compression strategy according to European Paediatric Soft tissue sarcoma Study Group recommendations. European Journal of Cancer, 2022, 161, pp.64-78. ⟨10.1016/j.ejca.2021.10.025⟩. ⟨hal-04027205⟩
• 
  Mario Campone, Thomas Bachelot, Isabelle Treilleux, Barbara Pistilli, Julia Salleron, et al.. A phase II randomised study of preoperative trastuzumab alone or combined with everolimus in patients with early HER2-positive breast cancer and predictive biomarkers (RADHER trial). European Journal of Cancer, 2021, 158, pp.169-180. ⟨10.1016/j.ejca.2021.09.017⟩. ⟨hal-03469622⟩

165

222